Pheon Therapeutics Ltd

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Pheon has just raised $120m in a series B round to fund early-stage trials of its new antibody drug conjugate technology, but is keeping the novel target’s identity under wraps for now, conscious of

AltruBio Inc. took a big step up from its $63m series A venture capital round in 2021 when it announced a series B round totaling up to $225m on 21 May, which will fund ongoing and planned Phase IIa

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda, F-star Sign Joint Research Pact